The impact of the termination override mutation on the activity of SSU72 by McCracken, Neil Andrew
 
 
 
 
THE IMPACT OF THE TERMINATION OVERRIDE MUTATION 
ON THE ACTIVITY OF SSU72 
 
 
 
Neil Andrew McCracken 
 
 
Submitted to the faculty of the University Graduate School  
in partial fulfillment of the requirements  
for the degree  
Master of Science  
in the Department of Biochemistry and Molecular Biology, 
Indiana University 
 
 
December 2016 
 
 
 
 
ii 
 
 
Accepted by the Graduate Faculty, Indiana University, in partial  
fulfillment of the requirements for the degree of Master of Science. 
 
  
 
Master’s Thesis 
Committee                  
 
_____________________________________ 
        Amber L Mosley, PhD. Chair 
 
 
 
_____________________________________ 
        Mark G. Goebl, PhD. 
 
 
 
                                             
 
                                               
_____________________________________ 
        Ronald C. Wek, PhD. 
 
 
 
 
 
 
 
 
iii 
 
ACKNOWLEDGEMENTS 
The following people played an instrumental role in the completion of this work and I am 
so very thankful for each of them. 
 Dr. Amber Mosley:  It was such a pleasure to be part of your lab family over the 
past two years. Your constant encouragement coupled with critique has allowed 
me to grow as a scientist more than any other period of time in my life. I also 
consider you a friend and will always appreciate your value of my opinion and 
how our discussions were like those of colleagues.  
  
 Dr. Mark Goebl:  Your roles as member of my committee and as a lecturer in my 
classes has taught me the importance of simplicity and practicality. I am also 
thankful for your help and guidance two years ago when I was first considered 
the graduate program.  
 
 Dr. Ron Wek:  You are my most favorite lecturer in all of my years of undergrad, 
graduate school and 15 years in industry. You make understanding the topic of 
protein expression achievable to a chemical engineer. At the same time, our 
discussions made me realize how much there really is for me to learn.  
 
 Whitney Smith-Kinnaman:  I feel like you were always looking out for me in the 
lab and the lab would not be a family without you.  
 
 Dr. Jerry Hunter:  I will never forget our weekends in the lab together when I first 
started the Master’s program. Your willingness to share lab methods with me 
were essential to this work.  
iv 
 
 
 My lab mates Sarah Peck, Jose Victorino, Dr. Mel Fox, Asha Boyd and Gabi 
Mazur:  You made school fun.  
 
 My daughter Ruby:  You bring me so much joy and I am so very lucky to have 
you call me daddy. I am thankful for each and every day that I have known you. 
While I never want you to grow up, I look forward to the days ahead as you 
become the absolutely amazing woman you were made to be. 
 
 My son Nolan:  You will always be my boy. I will never forget the day you were 
born and how it felt to hold you in my arms. You make me proud and I will always 
be your number one fan. Your laugh and sense of humor are contagious and 
your caring for other people will surely carry you far in life.  
 
 And most importantly, my wife Becca:  You will always be my love and best 
friend. The late nights and weekends in the lab or studying at the coffee shop 
would not have happened without you. You are the strongest woman I know. It is 
your strength and selflessness that have brought us through challenges while it is 
your joy and spirit that have made our walk through life enjoyable.  
 
 
 
 
 
v 
 
Neil Andrew McCracken 
THE IMPACT OF THE TERMINATION OVERRIDE MUTATION  
ON THE ACTIVITY OF SSU72 
Ssu72, an RNA Pol II CTD phosphatase that is conserved across eukaryotes, has been 
reported to have a wide array of genetic and physical associations with transcription 
factors and complexes in RNA transcription. Catalytic mutants of Ssu72 are lethal across 
many eukaryotes, and mutations to non-catalytic sites in SSU72 phosphatase have been 
shown to lower function. One spontaneous mutation of the SSU72 gene in 
Saccharomyces cerevisiae (A to C nucleotide mutation resulting in an L84F mutation in 
the coded protein) was shown to have transcription termination deficiency (termination 
override or TOV). This SSU72 mutation was suggested by Loya et al. to cause a 
lowering of the phosphatase activity of the protein and consequently affect proper 
termination. In research reported herein, an investigation was completed through in-vitro 
and ex-vivo approaches with the goal of understanding the impact of the SSU72 TOV 
mutation on the observed phenotype in S. cerevisiae. It can be concluded from work 
presented in this report that the SSU72 TOV mutation does not cause a decrease in in-
vitro phosphatase activity as compared to wild type. Evidence presented even suggests 
an increase in phosphatase activity as compared to wild type Ssu72. One model for the 
observed responses in transcription termination is that the phenylalanine substitution in 
Ssu72 leads to cooperative interactions with proline residues in the CTD. It is proposed 
that the corresponding increase in Ssu72 phosphatase activity limits RNA Pol II CTD 
association with termination factors, such as Nrd1, thus causing deficient transcription 
termination.  
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INTRODUCTION 
Transcription of DNA to RNA is the prerequisite step for all cellular functions as it creates 
the message (mRNA) that is later translated into proteins. In many cases, transcription 
produces non-coding RNAs (i.e. miRNA, lncRNA, snRNA and snoRNA) that are used for 
either the execution of transcriptional steps or other regulatory processes. Transcription 
of RNAs in eukaryotes is executed by three polymerases; RNA Polymerase I (hence Pol 
I), RNA Polymerase II (hence Pol II) and RNA Polymerase III (hence Pol III) (Cramer et 
al., 2008). Pol I is responsible for transcribing ribosomal RNA (excluding 5S rRNA), 
whereas Pol III transcribes transfer RNA (tRNA), 5S ribosomal RNA, and some small 
RNAs. Pol II is responsible for generating not only RNAs that can code for protein, pre-
messenger RNA (pre-mRNA), but also other non-coding RNAs that include small 
nuclear RNA (snRNA) and microRNA (miRNA).  
 
The transcription process by Pol II has been well characterized despite its complexity. 
DNA transcription by Pol II is traditionally broken down into the three phases of initiation, 
elongation and termination. Initiation corresponds with the docking of Pol II to the 
upstream portion of the gene that is to be transcribed. The genetic initiation region 
contains a variety of elements such as promotors, enhancers and silencers that 
stimulate or repress start site recognition by Pol II (Breathnach & Chambon, 1981; 
O'Shea-Greenfield & Smale, 1992; Riethoven, 2010; Smale, Schmidt, Berk, & Baltimore, 
1990). Other proteins, known as transcription factors, also act in partnership with Pol II 
to facilitate DNA site recognition, DNA binding promotion or interaction stabilization 
(Roeder, 1991). The general factors that are associated with initiation are TFIIA, TFIIB, 
TFIID, TFIIE, TFIIF and TFIIH. After Pol II has docked with the DNA template and the 
pre-initiation complex (PIC) is formed, the hydrogen bonds between nucleotides are 
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broken by the helicase activity of TFIIH (T. K. Kim, Ebright, & Reinberg, 2000). Melting of 
nucleotide bonds results in the formation of an open complex (Wang, Carey, & Gralla, 
1992), which allows RNA Pol II to initiate synthesis of the nascent RNA. Factors such as 
TFIIS, SWI/SNF, Spt4, Spt6, and FACT (Sims, Belotserkovskaya, & Reinberg, 2004) are 
then recruited to Pol II in order to progress to the next phase of transcription elongation 
(Bentley, 2002), while other factors are thought to remain behind but near the promoter 
to act as guides for re-initiation (Yudkovsky, Ranish, & Hahn, 2000; Zawel, Kumar, & 
Reinberg, 1995).  
 
The transition from initiation to the elongation phase has been suggested to be 
regulatory step in gene expression (T. H. Kim et al., 2005). At the point of transition, Pol 
II can go through steps of promoter escape, pausing, and “productive elongation” 
(Saunders, Core, & Lis, 2006). The success of the initiation to elongation transition is 
regulated by the presence of transcription activators/factors such as SWI/SNF (Brown, 
Imbalzano, & Kingston, 1996). If Pol II is indeed able to escape the promoter region and 
continue to elongation, nucleotides (NTPs) are added to the nascent transcript. In the 
process of elongation, Pol II is accompanied by factors that are both passive and active. 
Passive factors (e.g. the PAF complex) associate with Pol II for the duration of 
elongation while active factors (e.g. TFIIF) associate for short periods of time during 
elongation (Mayer et al., 2010; Sims et al., 2004).  
 
Prevention of downstream (and potentially undesired) gene transcription during 
transcript synthesis is of utmost importance during elongation.  Characterization of the 
transition from transcript elongation to termination is complicated by the fact that the 
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proposed model depends on whether the transcript is coding or non-coding (Porrua & 
Libri, 2015). In the case of mRNA, coordinated with Pol II separation from the DNA 
template, a chain of adenines is added to the 3’-end of the transcript (Richard & Manley, 
2009). Non-coding transcripts on the other hand, can require the participation of factors 
such as Nrd1, Nab3 and Sen1 (NNS) to aid in the termination process (Vasiljeva, Kim, 
Mutschler, Buratowski, & Meinhart, 2008). In general, the process of transcription 
termination requires the association of transcription factors with Pol II to regulate and aid 
in the disengagement of the polymerase from the DNA. A general pictorial description of 
the transcription process is shown in Figure 1. 
 
Figure 1. Model of Pol II transcription phases (yellow TF = Transcription Factors, blue EF 
= Elongation Factors, red TF = Termination Factors) 
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Many co-transcriptional activities are orchestrated by the C-terminal Domain (CTD) of 
subunit 1 of the 12 unit Pol II (S. Buratowski, 2009). The CTD is composed of heptad 
repeats (YSPTSPS) numbering 26 in budding yeast and 52 in vertebrates where the 
length of this unstructured domain has been associated with the complexity of the 
organism (Corden, Cadena, Ahearn, & Dahmus, 1985; Hsin & Manley, 2012). Besides 
initiation, elongation and termination, the CTD has been associated with other features 
of gene expression, including polyadenylation, 5'-capping, histone methylation, and pre-
mRNA splicing (Stephen Buratowski, 2003; McCracken, Fong, Yankulov, et al., 1997). In 
order for the polymerase to participate in this wide array of tasks, the CTD is 
phosphorylated at serine and tyrosine sites at different times during transcription to 
accommodate docking of proteins that assist in the many functions of gene expression 
that were discussed above. Chromatin Immunoprecipitation (ChIP) studies have 
revealed that serine 5 is predominantly phosphorylated at the beginning of gene 
transcription, whereas serine 2 and serine 7 of the CTD is phosphorylated toward when 
transcription elongation proceeds towards the 3’-end of the gene (Chapman et al., 2007; 
P. Komarnitsky, E.-J. Cho, & S. Buratowski, 2000; Mayer et al., 2010; Phatnani & 
Greenleaf, 2006). 
 
An illustration of the varying states of phosphorylation that are present through the 
phases of ranging from initiation (Jeronimo, Bataille, & Robert, 2013) to termination is 
shown in Figure 2 (where the deeper color indicates a phosphorylated serine).  
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Figure 2. Varying states of CTD phosphorylation based on stage of transcription 
One protein kinase that engages with Pol II, TFIIH, has specificity for phosphorylation of 
serine 5 (Philip Komarnitsky et al., 2000), and serine 5 has been shown through multiple 
methods to associate with factors participating the capping of pre-mRNAs (P. 
Komarnitsky, E. J. Cho, & S. Buratowski, 2000; McCracken, Fong, Rosonina, et al., 
1997). On the other hand, the protein kinase CTDK-I has been reported to engage with 
factors associating with the 3’ end of the mRNA and a subunit of a cleavage factor (CF 
IA) that binds to phosphorylated serine 2 in the CTD (Licatalosi et al., 2002). 
Furthermore, other subunits of the CF1A cleavage factor, Rna15, Rna14, Pcf11p, were 
also shown to associate with phosphorylated CTD (Barilla, Lee, & Proudfoot, 2001; B. 
Dichtl et al., 2002; Kyburz, Sadowski, Dichtl, & Keller, 2003).  
 
Just as phosphorylation of the serine residues of the CTD affects transcription, it is also 
understood that de-phosphorylation is necessary to maintain proper function of RNA Pol 
II. CTD phosphatases are responsible for removal of the phosphate at serine and 
threonine residues and some that have been identified include Fcp1 (Archambault et al., 
6 
 
1997), Scp1 (Yeo, Lin, Dahmus, & Gill, 2003) and Rtr1 (Mosley et al., 2009). Another 
CTD phosphatase, SSU72, was initially described as having genetic association with 
transcription factor IIB (TFIIB) in S. cerevisiae (Sun & Hampsey, 1996). Specifically, it 
was shown in this initial report by Sun et al. that a mutant of SSU72 was found to be an 
enhancer of a SUA7 defecta and that cysteine residues and the N-terminus of Ssu72 
were essential for function. Physical interactions between Ssu72 and RNA Pol II were 
also reported based on co-immunoprecipitation assays (Pappas & Hampsey, 2000). 
Association of Ssu72 with the 3’- end of DNA has been found as the protein was found 
to be stably associated with the RNA cleavage and polyadenylation factor (CPF) and 
was described to be a possible “bridge” between CPF subunits (Bernhard Dichtl et al., 
2002; Eduard Nedea et al., 2003). Overall, Ssu72 has the unique distinction of being 
associated with not only downstream transcription elongation but also the transition 
between elongation and termination. The mixed functionality of Ssu72 was further 
supported when the protein was described to have a phosphatase role independent of 
its CPF association. The identification of the phosphatase activity was based not only on 
structural motif of the protein (CX5R) (Meinhart, Silberzahn, & Cramer, 2003) but also on 
its specificity of Ssu72 for serine 5 of the CTD heptad repeats (Krishnamurthy, He, 
Reyes-Reyes, Moore, & Hampsey, 2004) and later specificity for serine 7 (Bataille et al., 
2012; Xiang, Manley, & Tong, 2012; D. W. Zhang et al., 2012) . Furthermore, it was 
reported that Ssu72 preferentially binds to the CTD of Pol II when cis-proline is present 
in the heptad repeats (Mayfield et al., 2015b; Werner-Allen et al., 2011) as opposed to 
trans-proline. The Ssu72 protein was more recently studied in Caenorhabditis elegans 
where it was found to not be requisite for viability (F. Chen et al., 2015). At the same 
                                                          
a SUA7 encodes for the transcription factor, TFIIB. The Ssu72 protein was found with other 
suppressors of a SUA7 defect and was therefore designated as a suppressor of SUA7. The 
SUA7 designation is a misnomer due to the fact that it was actually shown to be associated with 
enhancing a SUA7 defect. 
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time, Ssu72 was shown in C. elegans to be connected with regulation of alternative 
polyadenylation sites of pre-RNAs during neuronal development (F. Chen et al., 2015).  
 
Many of the functions described so far are conserved in mammals (St-Pierre et al., 
2005) and have consequently led to investigations that are more directed to translational 
applications. For instance, it was reported that one of the transcription elongation factors 
for the HIV-1 virus (Tat) associates directly with Ssu72 thus linking the phosphatase with 
viral gene expression in host cells (Y. Chen et al., 2014). Another report (St-Pierre et al., 
2005) used a yeast two-hybrid approach to show that Ssu72 physically associates with 
the human retinoblastoma tumor suppressor (pRb); a protein whose inactivation in 
human cells contributes to different forms of cancer (Liu, Dibling, Spike, Dirlam, & 
Macleod, 2004). Alignment of the Ssu72 protein in yeast with the human orthologue is 
shown below in Figure 3 and illustrates the conservation among these phosphatases as 
exemplified by the catalytic cysteine residue (highlighted in yellow) along with the other 
consensus in the sequences. 
 
Figure 3. Alignment between Ssu72 protein sequence in Baker’s yeast and Homo 
sapiens 
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Association of Ssu72 with both the 5’- and 3’- ends of transcribed genes has contributed 
to research on the role of Ssu72 in gene looping. It has been shown by several methods, 
including: genetic interactions between Ssu72 and the initiation factor TFIIB (Sun & 
Hampsey, 1996), electron microscopy (Morgan, 2002) and chromosome conformation 
capture (3C) (Tan-Wong et al., 2012), that the promoter regions and associated initiation 
factors can associate with the 3’ ends of the gene and its corresponding factors (such as 
the polyadenylation complex). The association between the two distal regions of a gene 
not only can aid in the efficiency of the transcriptional process for highly expressed 
genes but also potentially act to regulate the transcription of the sense versus antisense 
DNA template strand. Specifically, it was observed through 3C analysis that mutation of 
Ssu72 prevents formation of gene loops across a specific gene and also results in an 
increase in ncRNA expression (Tan-Wong et al., 2012). Therefore, Ssu72 was 
implicated in regulating the balance between transcription of coding and non-coding 
transcripts. An adapted model for Pol II transcription featuring Ssu72 is shown in Figure 
4. 
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Figure 4. Model of Pol II transcription phases with CPF and Ssu72 
 
As with many proteins, our understanding Ssu72 relies on observing the impact of 
conditional and/or non-lethal mutations of SSU72 on transcription. One such mutation 
(Loya, O'Rourke, & Reines, 2012) was found in a genetic screening of S. cerevisiae that 
had been transformed with a unique expression construct. Specifically, the introduced 
vector contained a strong intergenic terminator (IT) flanked on either side by a galactose 
inducible promoter and a GFP reporter. The goal of the experiment was to isolate 
mutants with ineffective termination as indicated by a higher level of fluorescence in 
FACS screening. Termination Override (TOV) mutants were sorted and two 
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spontaneous mutants were identified that coincidentally each contained identical 
mutations in the SSU72 gene. Specifically, an A to C mutation in the nucleotide 
sequence led to expression of the Ssu72 phosphatase with leucine at residue 84 
changed to a phenylalanine. Association between the L84F mutant Ssu72 protein and 
the corresponding termination deficient phenotype in-vivo was unclear but it was 
suggested that the mutation in some way lowered the phosphatase activity of the protein 
and consequently, impaired proper transcription termination (Loya et al., 2012).  
 
The SSU72 TOV mutation is of interest due to the fact that it implies an unknown 
function of the phosphatase or reinforces a previously identified function. The TOV 
mutant is also intriguing since the leucine to phenylalanine substitution in Ssu72 
potentially highlights the importance of a region in the protein that is downstream of the 
identified catalytic site (highlighted in Figure 3). Research presented herein seeks to 
explain the link between Ssu72 L84F and the observed TOV phenotype. Specifically, 
this work aims to show that the TOV phenotype is potentially the result of an increase in 
phosphatase activity of the L84F mutant Ssu72 when compared to wild type Ssu72 in 
assays using a small molecule substrate. The result of this increase in activity results in 
higher levels of de-phosphorylated RNA Pol II CTD with consequential lower association 
of termination factors (NNS complex) with the CTD of Pol II. The findings shown provide 
insight into the function of an essential phosphatase that plays a large number of roles in 
transcription.  
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MATERIALS AND METHODS 
I. Transformation of Wild Type plasmid DNA into E. coli 
Wild type SSU72 DNA (pGST-SSU72 wild type supplied by the Faye lab) was amplified 
by adding 1 microliter of dsDNA to a vial of One Shot® chemically competent E.coli 
cells. After gentle mixing, the mixture was incubated for five minutes at 2-8°C. The 
sample was then mixed with in an Eppendorf thermomixer at 42°C for 30 seconds. 250 
µL of S.O.C. Medium (Super Optimal Broth with Catabolite repression, Invitrogen part 
number 46-0700, lot 1141705) was then added to the tube and put into an incubator at 
37°C, shaking at 150 rpm (Innova 44 incubator). After approximately 1 hour of shaking, 
100 microliters of the transformation mix was transferred to a pre-warmed agar plate (LB 
+ ampicillin). Culture was spread across the plate and the plate was incubated overnight 
at ambient conditions. A single colony was inoculated into LB with ampicillin (0.7X). The 
culture was incubated at 37°C with shaking (150 rpm). The next day, the culture tube 
was removed from the incubator and the broth was centrifuged at 6800 rcf for 2 minutes 
(Eppendorf 5430R centrifuge).  
 
Plasmid DNA was isolated from the cells using a GeneJET Plasmid Miniprep Kit (part 
number K0503). Specifically, the cell pellet was re-suspended in 250 microliters of 
“Resuspension Solution” (with RNase A added). The solution was transferred to a 
centrifuge tube and 250 microliters of “Lysis Solution” was added and the sample was 
mixed. Next 350 microliters of “Neutralization Solution” was added to the sample and the 
mixture was clarified by centrifugation at 12000 rcf (at a higher rate for 5 minute. The 
supernatant was transferred to a GeneJET spin column, and 500 microliters of “Wash 
Solution” (diluted with ethanol prior to use) addition to the GeneJET column. The column 
was subjected to centrifugation at ~ 12,000 rcf (relative centrifugal force) or 30-60 
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seconds and the flow through was discarded. The wash step was repeated a second 
time and the tube was centrifuged an additional 1 minute to remove residual liquid. The 
spin column was transferred to a new centrifuge tube and 50 microliters of “Elution 
Buffer” was added to the column and incubated for 2 minute at room temperature 
followed by centrifugation for 2 minutes. “Elution Buffer” (50 microliters) was added to 
the column to elute more of the DNA. The plasmid DNA was retained for further use 
(referred to as p-SSU72 WT).   
 
II. Site Directed Mutagenesis 
An Agilent Quickchange Lightning Kit was used to conduct site directed mutagenesis of 
SSU72. Reactions were set up by combining 5 microliters of 10X “Reaction Buffer”, 10 – 
100 ng of dsDNA template (SSU72 WT DNA), forward primer (Table 1 and Table 2), 
reverse primer (Table 1 and Table 2), 1 microliter of dNTP mix, 1.5 microliters of 
QuikSolution reagent and high purity water to a final volume of 50 microliters. 1 microliter 
of “QuickChange Lightning Enzyme” was then added to the mix.  
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Table 1. Sequence of primers used in site directed mutagenesis of GST tagged 
constructs 
Primer Sequence 
SSU72_L84A_FORWARD 5’-ACGATCCAGCATTTGCAATGCACCGTTC-3’ 
SSU72_L84A_REV 5’-CCGTTACAAGTCGAACGGTGCATTGCAA-3’ 
SSU72_L84F_FORWARD 5’-CGATCCAGCATTTGCAAGAAACCGTTCG-3’ 
SSU72_L84F_REV 5’-GTTACAAGTCGAACGGTTTCTTGCAAATG-3’ 
ssu72 c15s F 5’-
ATTGTTGTTTGATGCAGAAACTGTGCAAAACTTCAAG
TTTGAATTGCG-3’ 
ssu72 c15s R 5’-
CGCATTTCAAACTTGAAGTTTTGCACAGTTTCTGCAT
CAAACAACAAT-3’ 
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Table 2. Details of primers used in site directed mutagenesis of GST tagged constructs 
Primer Primer 
Molecular 
Weight 
Tm (°C) Reconstituted 
Solution 
Concentration 
(mg/mL) 
Mass 
added to 
Reaction 
(ng) 
SSU72_L84A_FORWARD 12,256.0 68.0 1.16 mg/mL 125 
SSU72_L84A_REV 12,336.0 68.0 1.24 mg/mL 124 
SSU72_L84F_FORWARD 11,317.4 64.4 1.33 mg/mL 125 
SSU72_L84F_REV 11,419.4 64.4 1.16 mg/mL 125 
ssu72 c15s F 14,850.7 65.1 1.49 mg/mL 123 
ssu72 c15s R 14,677.6 65.1 1.47 mg/mL 125 
 
Reactions were cycled in a 96 well plate (Thermo Scientific AB3396) for the L84A and 
L84F constructs. The C15S construct was cycled in PCR tubes using the same 
thermocycler. Thermocycling was completed using an Eppendorf Mastercycler® Pro 
thermocycler with the parameters detailed below in Table 3. 
Table 3. Thermocycler program for site directed mutagenesis 
Segment Cycles Temperature (°C) Time 
1 1 95 2 minutes 
2 18 95 20 seconds 
60 10 seconds 
68 2 min, 48 sec 
3 1 68 5 minutes 
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Identities of the final plasmids are described below in Table 4. 
Table 4. Plasmid construct descriptions 
Construct Plasmid Identity 
SSU72 C15S p-SSU72 C15S 
SSU72 L84F p-SSU72 L84F 
SSU72 L84A p-SSU72 L84A 
 
III. Transformation of Rosetta Cells with SSU72 plasmids and glycerol stock 
preparation 
Rosetta 2(DES) pLys(s) cells (20 microliters) were transferred to a 1.5 mL Eppendorf 
tube and the applicable plasmid DNA (per Table 5 below) was dispensed into the tube 
with the cells. The mixture was incubated on ice for 5 minutes and the tube was heat 
shocked in a 42°C for 30 seconds and then placed back into ice for 2 minutes. S.O.C. 
Medium (80 microliters) was added to the tube and 50 microliters of the cells were 
transferred to a pre-warmed agar plates with chloramphenicol and ampicillin antibiotic 
(spread by sterile glass beads). Plates were allowed to incubate at room temperature 
overnight. A culture tube with 2 mL of LB, 1X ampicillin and 1X chloramphenicol and the 
tube was inoculated with a single colony from the plate that had been incubated. The 
tube was incubated at 37°C with agitation at 150 rpm (Innova 44 incubator). Glycerol 
stocks of the cell lines were prepared and stored at -80°C. A table of the stocks prepared 
is shown below in Table 5. 
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Table 5. Details of transformation for each construct 
Stock ID SSU72 Construct Source 
Plasmid 
Mass Used in 
Transformation (ng) 
pAM305 GST-SSU72 L84F p-SSU72 L84F 55.3 
pAM306 GST-SSU72 L84A p-SSU72 L84A 51.6 
pAM311 GST-SSU72 WT p-SSU72 WT 56.0 
pAM312 GST-SSU72 C15S p-SSU72 C15S 101.1 
           
IV. DNA Sequencing 
The sequence of the mutated DNA was confirmed through third-party Sanger 
Sequencing (Genewiz). The details of these submissions along with the sequencing 
primer used with the samples are described in Table 6 and Table 7 below. 
Table 6. Details of Genewiz Sequencing 
Stock ID SSU72 Construct Genewiz Tracking 
Number 
pAM305 GST-SSU72 L84F 10-309331369 
pAM306 GST-SSU72 L84A 10-309331369 
pAM311 GST-SSU72 WT 10-308769049 
pAM312 GST-SSU72 C15S 10-311165623 
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Table 7. Genewiz sequencing primer details 
Primer 
Number Sequence Name Sequence Tm °C 
P15-56 GST_544 TO 563 CGT ATT GAA GCT ATC CCA CA 52 
 
V. GST-SSU72 Expression in Escherichia coli and Affinity Purification 
Starter cultures were generated by inoculating a small volume of LB (i.e. 1 – 5 mL), 1X 
ampicillin/1X chloramphenicol with glycerol stock from the applicable construct (i.e. 
pAM305, pAM306, pAM311, pAM312). Starter culture was incubated several hours to 
overnight at 37°C and used to inoculate 1L of the same LB/antibiotic broth (in a 2L 
Erlenmeyer flask). Culture was grown to OD600 of at least 0.8 followed by addition of 1 
mM IPTG at which point the incubation temperature was shifted to 18°C. After overnight 
protein expression, cells in the 1L broth were pelleted (Thermo Scientific Sorvall RC6+ 
centrifuge with rotor F9-4x1000y) and the pellet was re-suspended in lysis buffer (50 mM 
HEPES, 150 mM NaCl, 10% Glycerol, 10 mM EDTA, 1 mM β-mercaptoethanol) 
supplemented with 1 mM PMSF and 0.1% Triton X-100. The cells were then transferred 
to a chilled pressure cell that was set in a French Press manifold and cells were lysed 
three times at a pressure of ~ 1000 psi (high setting). Lysates were clarified by 
centrifugation using a Thermo Scientific Sorvall RC6+ centrifuge (with rotor F13-
14x50cy) at 13,000 rpm for 60 minutes and the supernatant liquid was loaded onto a 
Biorad column packed with 1 mL of Glutathione Sepharose 4B resin (GE Healthcare). 
The loading occurred at a rate of 1 mL/min using the Biorad chromatography system. 
After loading, the column was washed with a wash buffer solution (50 mM HEPES, 300 
mM NaCl, 10% Glycerol, 10 mM EDTA and 1 mM β-mercaptoethanol). Specifically a 
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gradient of lysis buffer to 100% wash buffer was used at a rate of 1 mL/min for 30 
minutes (lysis buffer to wash buffer). After 30 minutes, the column was washed with 
100% wash buffer for another 30 minutes. After washing, the GST tagged protein was 
eluted from the column using an elution buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 10 
mM EDTA, 0.1-1 mM β-mercaptoethanol, 100 mM R-glutathione). Elution was 
conducted using an increasing gradient of elution buffer at a rate of 1 mL/min (lysis 
buffer to elution buffer). Elution fractions (1 mL each) were collected each minute as the 
UV absorbance was recorded. Fractions were combined based on the recorded 
absorbance and the combined fractions were transferred to a 7000 MWCO dialysis tube. 
Dialysis occurred overnight at 2-8°C in 5L of dialysis buffer (50 mM HEPES, 150 mM 
NaCl, 1 mM DTT). The next day, the dialysate was transferred to a 10 kD spin filter and 
the solution was concentrated to around 1 mL. Glycerol was added to the stock (around 
10% of the total volume) and the stock was stored at -80°C for future use or analysis.  
    
VI. Protein Analysis by SDS-PAGE and Coomassie Stain 
SDS-PAGE gels were prepared per the recipe shown below in Table 8. Gels were 
loaded with Biorad Precision dual color standard and samples to be analyzed were 
diluted as desired with SDS running buffer and heat denatured at 100°C for 
approximately 5 minutes. A BSA protein standard was also used and was loaded into 
appropriate wells in the gel for estimation of protein concentrations. 
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Table 8. SDS-PAGE gel formulation 
Component Stacking Component Separating 
30% Polyacrylamide 
(mL) 
1.36 30% Polyacrylamide 
(mL) 
10 
1M Tris (pH 6.8) (mL) 1 1M Tris (pH 8.8) (mL) 7.5 
10% Ammonium 
persulfate (mL) 
0.08 10% Ammonium 
persulfate (mL) 
0.2 
20% SDS (mL) 0.04 20% SDS (mL) 0.1 
TEMED (mL) 0.008 TEMED (mL) 0.008 
Water (mL) 5.44 Water (mL) 4.6 
    
Total (mL) 7.928 Total (mL) 22.408 
Gel % SDS 5 Gel % SDS 13 
 
Electrophoresis was conducted using a SDS gel box and 1X TGS buffer. Gels 
electrophoresis for 45 minutes at 200 volts. Proteins separated in the gels were stained 
with Coomassie stain and de-stained overnight with a solution containing 7% methanol 
and 6% glacial acetic acid. Stained proteins were visualized using an Epson V700 
scanner and gel concentrations were estimated using the ImageJ open source program. 
 
VII. GST Tag Removal 
Purified GST-Ssu72 WT construct were thawed along with GST-3C prepared by Asha 
Boyd on 8/28/15. Purified WT construct (375 microliters) was added to a 1.5 mL 
Eppendorf tube. Approximately 1000 microliters of chilled cleavage buffer solution (10 
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mM Tris-HCl pH 8, 150 mM NaCl, 0.1% IGEPAL CA-630, and 0.5 mM EDTA (pH 8)) 
was added to the Ssu72 WT construct along with 10 microliters of the GST-3C protease. 
The sample was agitated overnight via rotisserie.  
 
A Biorad column was packed with 1 mL of Glutathione Sepharose 4B beads and 
cleavage buffer was used in this process of preparing the column for use. The column 
was washed with water purified by a Sartorius system followed by wash with cleavage 
buffer. The column was loaded with the cleaved Ssu72 recombinant protein at a flow 
rate of 1 mL/min. Cleavage protein was collected during this rinse. The GST was then 
eluted from the column through an elution buffer solution of 150 mM NaCl, 40 mM 
EDTA, 50 mM HEPES, and 100 mM reduced L-glutathione adjusted to pH 7.6. The 
protein was collected and concentrated in a 10kD spin filter prior to further analysis.  
 
VIII. In-Vitro Ssu72 Phosphatase Activity Assay 
The phosphatase assay was completed in a Costar black 96 well plate. Each well was 
filled with Molecular Biology grade water to achieve a final volume of 100 - 350 µL 
depending on the experiment, 250 mM succinic acid, pH 6.0 (to a final concentration of 
50 mM), 5M NaCl (to a final concentration of 150 mM NaCl), dialysis buffer solution (per 
the composition described in the expression section) sufficient to achieve equivalent 
volume of Ssu72 protein solution added to each well in the case that multiple constructs 
is tested, Ssu72 protein and a final concentration of 10 µM 6,8-difluoro-4-
methylumbelliferyl phosphate (DiFMUP) in DMSO. After addition of DiFMUP, the plate 
was analyzed in a Molecular Devices Spectramax® M5 plate reader set at 30°C with 
excitation at 355 nm and emission at 455 nm.  
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IX. Biotinylated CTD peptide pulldown experiments 
The pulldown protocol was adapted from the procedure from the manufacturer of the 
Dynabeads® (Invitrogen). 2.5 μg of biotinylated CTD peptide (four heptad repeats) was 
incubated with 0.5 mg of Invitrogen Dynabeads® M280 Streptavidin in binding buffer (50 
mM Tris-HCl pH 6.5, 300mM NaCl, 1 mM dithiothreitol, 0.5% IGEPAL CA-630, 1mM 
PMSF) at 4 °C for 2 hours on a rotisserie. Recombinant GST-Ssu72 (approximately 10 
µg) and 100 μg of BSA to the micro centrifuge tube were then added to the respective 
tubes and incubated for another 3 hours at 4°C. Samples were then inserted into a 
magnetic separation rack. Beads were given ample time to separate from the 
supernatant and the liquid was removed via pipette. The beads were then washed four 
times with 1 ml binding buffer containing 10 μg/mL BSA and in each case, previously 
mentioned magnetic separation and liquid removal methods were used. Post wash, 100 
μl of 4x SDS-loading buffer was added to each of the tubes and each were incubated in 
a heat block at 100°C for 5 minutes to separate biotinylated protein from Streptavidin 
beads. Beads were separated from the liquid using the magnetic rack and the 
supernatant liquid was retained for analysis. 
 
X. Expression and Purification of Ssu72-3xFLAG in Saccharomyces cerevisiae  
Log-phase yeast cells expressing Ssu73-3XFLAG were collected by centrifugation using 
rotor the RC6+ floor centrifuge at 4000 x g for 10 minutes. The cell pellet was washed 
with high purity water and re-suspended in 25mL of TAP lysis buffer (40mM HEPES-
KOH, pH 7.5, 10% glycerol, 350mM NaCl, 0.1% Tween-20, 1X fresh yeast protease 
inhibitors solution per 2.5 grams of pellet). Cells were lysed by grinding in a Waring 
blender with dry ice after freezing in liquid nitrogen. Lysates were thawed and the 
resulting extract was treated with 100 units of DNAse I and 10 microliters of 30 mg/mL 
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heparin for 10 minutes at room temperature. The extract was then centrifuged at 14,000 
x g for 1 hour in 50mL conical tubes in the RC6+ centrifuge to pellet the remaining debris 
(sample remaining in supernatant). Anti-FLAG agarose resin (500 µL) was washed with 
1.5 mL TAP lysis buffer in a micro centrifuge tube and the resin was re-suspended in 
500uL TAP lysis buffer. The 50mL conical tubes were removed from the centrifuge once 
centrifugation was complete and clarified lysate was decanted to a clean vessel. 
Washed anti-FLAG agarose (Sigma) was added to the lysate and incubated on a stir 
plate overnight at 4C.  After an overnight incubation, the cell suspension was 
transferred to a 30mL Bio-Rad Econoprep column and drained by gravity flow. Beads 
retained in the column were then washed with 120 mL TAP lysis buffer solution by 
gravity flow. FLAG peptide (125 µL) was added to resin in the column followed by 
incubation for 5 minutes (using a cap on the outlet of the column to prevent draining). 
Liquid in the column was then eluted by gravity. 125 uL of TAP lysis buffer was used to 
wash the resin (combined wash and elution were labeled as elution 1). Elution and wash 
steps were then repeated five times and eluted aliquots were stored at -80°C until 
needed. Each elution after elution 1 was labeled sequentially E2 through E6. 
 
XI. Protein Analysis by SDS-PAGE and Silver Stain 
Samples from the yeast expression and purification study were analyzed by SDS-PAGE 
followed by silver staining. Purified samples were first diluted 1:1 with SDS-PAGE 
running buffer (20 microliters of elution sample with 20 microliters of 2X SDS Loading 
Buffer) followed by denaturation at 100 °C for 5 minutes. Denatured samples in a volume 
of 20 µL were loaded into a Bio-Rad Mini Protean® precast gel and electrophoresis was 
performed in a SDS polyacrylamide gel box filled with 1X TGS buffer at 200 volts for 35 
minutes. Following electrophoresis, gels were removed from the assembly and covered 
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with ~100mL of fixing solution at room temperature overnight. Fixing solution was 
discarded and ~ 100mL of ethanol wash was added to the container at room 
temperature with rocking for around 10 minutes. Ethanol wash was discarded and 
~100mL of Sartorius water was added with rocking for about 10 minutes. Water was 
discarded and ~100mL of Sensitizer Solution was added, followed by rocking for ~10 
minutes. Sensitizer solution was discarded and ~100mL of Sartorius water was at room 
temperature for 10 minutes. Water wash was discarded and ~100mL of silver nitrate 
solution was added with rocking for ~10 minutes. Silver nitrate solution was discarded 
with ~ 100 mL of Sartorius water added to the container. The gel was washed with 
rocking for ~5 minutes. Water was discarded and ~100mL of fresh developing solution 
was added with mild agitation for several minutes until the desired development of the 
gel was reached. Developing solution was discarded at this point and the gel staining 
was quenched using stop solution for 10 minutes. Stop solution was then removed and 
the gel was stored in water until imaged for documentation. Formulations for the 
solutions used in this work are summarized below in Table 9. 
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Table 9. Silver Stain Stock Formulations 
Stock Composition 
Fixing Solution 30% Ethanol 
10% Acetic Acid 
60% Water 
Ethanol Wash 30% Ethanol 
70% Water 
Sensitizer Solution 0.02% Sodium Thiosulfate (2% Solution) 
99.98% Water 
Silver Nitrate Solution 0.1% Silver Nitrate 
0.02% Formaldehyde 
99.9% Water 
Developing Solution 2.5% Sodium Carbonate 
0.05% Formaldehyde 
0.005% Sodium Thiosulfate 
97.445% Water 
Stop Solution 0.5% Glycine 
99.5% Water 
 
 
XII. Analysis of 3xFLAG WT Ssu72 by LC-MS/MS  
These experiments were performed as previously described (Smith-Kinnaman et al., 
2014). Two of the elutions (2 and 3) from the S. cerevisiae expression and purification in 
section X (100 µL of each) were combined in a micro centrifuge tube and 200 µl of cold 
solution of 100 mM Tris-HCl (pH 8.5) was added. Trichloroacetic Acid (100 µL) was then 
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added to the tube and mixed overnight at 4°C to precipitate the protein. The pellet was 
collected by centrifugation at 14,000 rpm for 30 min at 4°C (Thermo Scientific Sorvall 
RC6+ centrifuge with rotor F13-14x50cy). The supernatant was discarded and 500 µl of 
cold acetone was added to the pellet and mixed by vortexing. The pellet was collected 
by centrifugation for 10 min at 4°C at 14,000 rpm; the acetone wash was repeated once 
more in order to remove the TCA. After the second wash was decanted, the tube was 
left open to allow acetone to evaporate from the pellet. After precipitation was complete, 
the sample was ready for digestion. First 30 µl of solution of 8M Urea in 100 mM Tris-
HCl (pH 8.5) was added to the TCA-precipitant. A 1.5 µL aliquot of 1 M Tris (2-
carboxyethyl) phosphine hydrochloride (TCEP) was then added to the tube to achieve a 
final concentration of 50 mM TCEP. This step was conducted in order to reduce the 
disulfide bonds of the protein. After TCEP addition, the contents of the mixture was 
incubated at room temperature for 30 minutes. A 0.6 µL aliquot of 0.5M chloroacetamide 
(CAM) was added to the reduced mixture to a final concentration of 10mM CAM, and 
incubated at room temperature for 30 min in the dark. The CAM addition was used to 
alkylate reduced bonds in order to prevent oxidation. Endoproteinase Lys-C (0.3 µL of 
0.2µg/µl solution in water) was added to the alkylated mixture and incubated at 37°C 
with shaking overnight. Post proteolytic cleavage, 90 µL of 100mM Tris-HCl, pH 8.5 was 
added to the mixture to dilute Urea to 2M followed by addition of 0.6 µL 1M CaCl 2 (final 
concentration 2mM). Trypsin (0.5 µg) was added with further overnight incubation at 
37°C and the cleavage reaction was quenched the next day with 7 µL formic acid. 
 
Column loading was conducted using a procedure described previously (Florens & 
Washburn, 2006). A fused silica glass column was packed with two different resins via a 
high pressure vessel and resin suspended in methanol. Packing consisted of 8.5 cm of 
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reverse phase C18 (Phenomonex Aqua®), 2.5 cm of strong cation exchange resin 
(Phenomonex Luna®) and 2.25 cm of C18. Post packing, the column was rinsed with 
buffer A solution (5% acetonitrile and 0.1% formic acid) and loaded with the 
digested/quenched Ssu72 sample. The column was then rinsed again with buffer A 
solution after loading in preparation for analysis. The Ssu72 protein was eluted from the 
column using a Proxeon nano-liquid chromatograph (LC). The LC was in-line with a 
ThermoFisher LTQ Velos linear ion trap mass spectrometer (MS). Elution from the 
column was analyzed using a 10-step multi-dimensional protein identification technology 
(MudPIT) method. Separation of components in the loaded column was accomplished 
by a gradient elution from buffer A (5% acetonitrile, 0.1% formic acid) to buffer B (80% 
acetonitrile, 0.1% formic acid). Mass spectra were analyzed with Scaffold (version 4) 
where Steps 2 through 4 of the data set were queried further while using a 5.0% peptide 
false discovery rate (FDR), 95% protein threshold and 2 minimum peptides to identify. 
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  RESULTS 
I. Sequencing 
The sequence of the four GST-SSU72 constructs was confirmed by Sanger Sequencing 
(Genewiz) in order to confirm that the plasmid mutations were correct for each of the 
constructs. The results reported by Genewiz aligned with SSU72 (S288C) are shown 
below in Figure 5. The results confirmed that the desired mutations were achieved by 
site directed mutagenesis. 
 
CLUSTAL O (1.2.1) multiple sequence alignment 
 
 
SSU72            -----------------------ATGCCTAGTCATCGCAATTCAAACTTGAAGTTTTGCA 
pAM311-WT        CCCTGGGATCCCCGGAATTCCGGATGCCTAGTCATCGCAATTCAAACTTGAAGTTTTGCA 
pAM312-C15S      CCCTGGGATCCCCGGAATTCCGGATGCCTAGTCATCGCAATTCAAACTTGAAGTTTTGCA 
pAM306-L84A      CCCTGGGATCCCCGGAATTCCGGATGCCTAGTCATCGCAATTCAAACTTGAAGTTTTGCA 
pAM305-L84F      CCCTGGGATCCCCGGAATTCCGGATGCCTAGTCATCGCAATTCAAACTTGAAGTTTTGCA 
                                        ************************************* 
 
SSU72            CAGTTTGTGCATCAAACAACAATCGTTCAATGGAATCGCATAAAGTCCTGCAAGAAGCAG 
pAM311-WT        CAGTTTGTGCATCAAACAACAATCGTTCAATGGAATCGCATAAAGTCCTGCAAGAAGCAG 
pAM312-C15S      CAGTTTCTGCATCAAACAACAATCGTTCAATGGAATCGCATAAAGTCCTGCAAGAAGCAG 
pAM306-L84A      CAGTTTGTGCATCAAACAACAATCGTTCAATGGAATCGCATAAAGTCCTGCAAGAAGCAG 
pAM305-L84F      CAGTTTGTGCATCAAACAACAATCGTTCAATGGAATCGCATAAAGTCCTGCAAGAAGCAG 
                 ****** ***************************************************** 
 
SSU72            GCTATAATGTTAGCTCTTACGGAACAGGTTCAGCTGTGAGACTGCCTGGTCTATCGATAG 
pAM311-WT        GCTATAATGTTAGCTCTTACGGAACAGGTTCAGCTGTGAGACTGCCTGGTCTATCGATAG 
pAM312-C15S      GCTATAATGTTAGCTCTTACGGAACAGGTTCAGCTGTGAGACTGCCTGGTCTATCGATAG 
pAM306-L84A      GCTATAATGTTAGCTCTTACGGAACAGGTTCAGCTGTGAGACTGCCTGGTCTATCGATAG 
pAM305-L84F      GCTATAATGTTAGCTCTTACGGAACAGGTTCAGCTGTGAGACTGCCTGGTCTATCGATAG 
                 ************************************************************ 
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SSU72            ATAAGCCTAATGTGTACTCATTTGGTACACCCTATAATGATATATATAATGATCTTTTAT 
pAM311-WT        ATAAGCCTAATGTGTACTCATTTGGTACACCCTATAATGATATATATAATGATCTTTTAT 
pAM312-C15S      ATAAGCCTAATGTGTACTCATTTGGTACACCCTATAATGATATATATAATGATCTTTTAT 
pAM306-L84A      ATAAGCCTAATGTGTACTCATTTGGTACACCCTATAATGATATATATAATGATCTTTTAT 
pAM305-L84F      ATAAGCCTAATGTGTACTCATTTGGTACACCCTATAATGATATATATAATGATCTTTTAT 
                 ************************************************************ 
 
SSU72            CACAATCAGCAGACCGTTACAAGTCGAACGGTTTATTGCAAATGCTGGATCGTAATAGAA 
pAM311-WT        CACAATCAGCAGACCGTTACAAGTCGAACGGTTTATTGCAAATGCTGGATCGTAATAGAA 
pAM312-C15S      CACAATCAGCAGACCGTTACAAGTCGAACGGTTTATTGCAAATGCTGGATCGTAATAGAA 
pAM306-L84A      CACAATCAGCAGACCGTTACAAGTCGAACGGTGCATTGCAAATGCTGGATCGTAATAGAA 
pAM305-L84F      CACAATCAGCAGACCGTTACAAGTCGAACGGTTTCTTGCAAATGCTGGATCGTAATAGAA 
                 ********************************   ************************* 
 
SSU72            GACTCAAAAAAGCACCTGAAAAATGGCAAGAAAGTACAAAAGTCTTCGACTTCGTTTTCA 
pAM311-WT        GACTCAAAAAAGCACCTGAAAAATGGCAAGAAAGTACAAAAGTCTTCGACTTCGTTTTCA 
pAM312-C15S      GACTCAAAAAAGCACCTGAAAAATGGCAAGAAAGTACAAAAGTCTTCGACTTCGTTTTCA 
pAM306-L84A      GACTCAAAAAAGCACCTGAAAAATGGCAAGAAAGTACAAAAGTCTTCGACTTCGTTTTCA 
pAM305-L84F      GACTCAAAAAAGCACCTGAAAAATGGCAAGAAAGTACAAAAGTCTTCGACTTCGTTTTCA 
                 ************************************************************ 
 
SSU72            CTTGTGAAGAGAGATGTTTTGATGCCGTTTGTGAAGATTTGATGAATAGAGGTGGGAAAT 
pAM311-WT        CTTGTGAAGAGAGATGTTTTGATGCCGTTTGTGAAGATTTGATGAATAGAGGTGGGAAAT 
pAM312-C15S      CTTGTGAAGAGAGATGTTTTGATGCCGTTTGTGAAGATTTGATGAATAGAGGTGGGAAAT 
pAM306-L84A      CTTGTGAAGAGAGATGTTTTGATGCCGTTTGTGAAGATTTGATGAATAGAGGTGGGAAAT 
pAM305-L84F      CTTGTGAAGAGAGATGTTTTGATGCCGTTTGTGAAGATTTGATGAATAGAGGTGGGAAAT 
                 ************************************************************ 
 
SSU72            TAAACAAAATAGTGCATGTAATTAATGTTGACATTAAAGATGATGATGAAAATGCTAAAA 
pAM311-WT        TAAACAAAATAGTGCATGTAATTAATGTTGACATTAAAGATGATGATGAAAATGCTAAAA 
pAM312-C15S      TAAACAAAATAGTGCATGTAATTAATGTTGACATTAAAGATGATGATGAAAATGCTAAAA 
pAM306-L84A      TAAACAAAATAGTGCATGTAATTAATGTTGACATTAAAGATGATGATGAAAATGCTAAAA 
pAM305-L84F      TAAACAAAATAGTGCATGTAATTAATGTTGACATTAAAGATGATGATGAAAATGCTAAAA 
                 ************************************************************ 
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SSU72            TTGGTAGCAAAGCTATATTGGAATTAGCTGATATGCTCAATGATAAAATAGAACAATGTG 
pAM311-WT        TTGGTAGCAAAGCTATATTGGAATTAGCTGATATGCTCAATGATAAAATAGAACAATGTG 
pAM312-C15S      TTGGTAGCAAAGCTATATTGGAATTAGCTGATATGCTCAATGATAAAATAGAACAATGTG 
pAM306-L84A      TTGGTAGCAAAGCTATATTGGAATTAGCTGATATGCTCAATGATAAAATAGAACAATGTG 
pAM305-L84F      TTGGTAGCAAAGCTATATTGGAATTAGCTGATATGCTCAATGATAAAATAGAACAATGTG 
                 ************************************************************ 
 
SSU72            AAAAAGATGACATTCCCTTTGAAGATTGTATAATGGACATTTTAACTGAGTGGCAAAGCT 
pAM311-WT        AAAAAGATGACATTCCCTTTGAAGATTGTATAATGGACATTTTAACTGAGTGGCAAAGCT 
pAM312-C15S      AAAAAGATGACATTCCCTTTGAAGATTGTATAATGGACATTTTAACTGAGTGGCAAAGCT 
pAM306-L84A      AAAAAGATGACATTCCCTTTGAAGATTGTATAATGGACATTTTAACTGAGTGGCAAAGCT 
pAM305-L84F      AAAAAGATGACATTCCCTTTGAAGATTGTATAATGGACATTTTAACTGAGTGGCAAAGCT 
                 ************************************************************ 
 
SSU72            CACATTCTCAACTACCGTCATTATACGCTCCTTCATATTACTAA---------------- 
pAM311-WT        CACATTCTCAACTACCGTCATTATACGCTCCTTCATATTACTAACCGCTCGAGCGGCCGC 
pAM312-C15S      CACATTCTCAACTACCGTCATTATACGCTCCTTCATATTACTAACCGCTCGAGCGGCCGC 
pAM306-L84A      CACATTCTCAACTACCGTCATTATACGCTCCTTCATATTACTAACCGCTCGAGCGGCCGC 
pAM305-L84F      CACATTCTCAACTACCGTCATTATACGCTCCTTCATATTACTAACCGCTCGAGCGGNCGC 
                 ********************************************                 
Figure 5. Nucleotide Sequence Alignment for Ssu72 Constructs 
 
 
II. Expression and Purification of GST-Tagged Ssu72  
Individual batches of LB broth were inoculated using glycerol stocks from pAM305 (L84F 
mutant), pAM306 (L84A mutant), pAM311 (WT) and pAM312 (C15S mutant) 
respectively. Starter cultures were grown followed by induction and expression. Cell lysis 
was conducted and the proteins were purified using a Biorad system. Absorbance over 
time at 280 nm is shown below for each of the four constructs (Figure 6, Figure 7, Figure 
8, and Figure 10).  
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Figure 6. Chromatogram for Loading, Wash and Elution of GST-Tagged Ssu72 (Wild 
Type) 
 
Figure 7. Chromatogram for Loading, Wash and Elution of GST-Tagged Ssu72 (C15S) 
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Figure 8. Chromatogram for Loading, Wash and Elution of GST-Tagged Ssu72 (L84F) 
 
 
Figure 9. Chromatogram for Loading, Wash and Elution of GST-Tagged Ssu72 (L84A) 
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A total of six separate replicate purifications of protein constructs were prepared using 
this procedure for the later evaluation by DiFMUP-based phosphatase assays. These 
batches included WT Ssu72, C15S, two biological replicates of L84A and two biological 
replicates of L84F. 
 
III. Analysis of GST Tagged Ssu72 Protein by SDS-PAGE and Coomassie Stain 
The GST-Ssu72 constructs were analyzed by SDS-PAGE, followed by Coomassie 
staining. Bovine serum albumin was also analysis by gel electrophoresis at varying 
concentrations in order to estimate concentration of each purified Ssu72 sample. 
Proteins were visualized by silver staining, which were analyzed using ImageJ analysis 
software in order to approximate concentration of each purified sample. Gels along with 
the calculated concentrations of each recombinant Ssu72 protein were shown below in 
Figure 10 through Figure 12.  
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Figure 10. SDS-PAGE, Coomassie stain of GST Ssu72 WT, C15S, L84A, L84A2, L84F, 
Cleaved WT, GST 
Protein Dilution Intensity
Protein 
Amount 
(µg) Sample (mL)
Protein 
Concentration 
Adjusted for Dilution 
(mg/mL)
GST Ssu72 WT 20 12267.21 689.9 0.001 13.8
GST Ssu72 C15S 15 11803.08 657.1 0.001 9.9
GST Ssu72 L84A 15 11116.62 608.5 0.001 9.1
GST Ssu72 L84A2 10 9493.426 493.5 0.001 4.9
GST Ssu72 L84F 5 11328.43 623.5 0.001 3.1
Ssu72 WT 4 7455.719 349.3 0.001 1.4
GST 5 10453.79 561.5 0.001 2.8
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Figure 11. SDS-PAGE, Coomassie stain of GST Ssu72 L84F#2, WT (with smaller 
molecular weight bands) 
 
Figure 12. SDS-PAGE, Coomassie stain calculations of GST Ssu72 L84F#2, WT 
(without smaller molecular weight bands) 
Protein Dilution Intensity
Protein 
Amount 
(µg) Sample (mL)
Protein 
Concentration 
Adjusted for Dilution 
(mg/mL)
L84F-2 2 35871.49 2855.7 0.001 5.7
L84F-2 5 18388.38 1262.3 0.001 6.3
L84F-2 10 10610.36 553.4 0.001 5.5
L84F-2 15 5654.61 101.7 0.001 1.5
L84F-2 20 3562.246 -89.0 0.001 -1.8
WT-2 20 9798.355 479.4 0.001 9.6
Protein Dilution Intensity
Protein 
Amount 
(µg) Sample (mL)
Protein 
Concentration 
Adjusted for Dilution 
(mg/mL)
L84F-2 2 11295.43 1127.6 0.001 2.3
L84F-2 5 6296.184 454.8 0.001 2.3
L84F-2 10 3883.527 130.1 0.001 1.3
L84F-2 15 2174.627 -99.9 0.001 -1.5
L84F-2 20 1396.92 -204.6 0.001 -4.1
WT-2 20 6506.648 483.1 0.001 9.7
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IV. Removal of GST Tag from Ssu72 protein 
In order to determine if the GST tag was impacting the activity of the phosphatase in the 
DiFMUP assay, the GST tag was removed from WT GST-Ssu72. In accomplish this 
removal, the purified GST-Ssu72 WT construct was first combined with GST-3C 
protease in cleavage buffer. After overnight cleavage, the cleaved protein was purified 
using a column packed with Glutathione Sepharose 4B beads. During the loading step of 
this purification, column was accidentally drained due to not shutting off the pump in 
time. Despite this issue, the column was rinsed with elution buffer and the eluted 
material was concentrated using a 10kD centrifuge filter. The purified protein was later 
analyzed by SDS-PAGE along with Coomassie staining to determine relative protein 
concentration. Results from this analysis are shown below in Figure 13 and demonstrate 
that the desired cleavage of the protein was achieved and that two proteins of different 
size were isolated. The slightly slower migrating bands in lanes 2 and 3 were confirmed 
to separate further by gel electrophoresis than the later migrating bands in lanes 4 and 
5. Bands were near the 25 kD ladder band and were representative of the 23 kD Ssu72 
and 26 kD GST.  
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Figure 13. SDS-PAGE and Coomassie stain of Ssu72 and GST following GST tag 
cleavage 
 
V. Assay of Phosphatase Activity In-Vitro 
In the first experiment, relative fluorescence response was recorded for the four Ssu72 
proteins (WT, C15S, L84A, L84A-2 and L84F). The Ssu72 proteins ranged in 
concentration from 0.01, 0.1, 1.0 and 10.0 µM and were analyzed in quadruplicate with 
DiFMUP at 10 µM (per conditions described in section VIII). In all experiments, WT 
Ssu72 was used as a positive control while C15S Ssu72 was used as a negative control. 
Fluorescence was measured by the plate reader and results are in Figure 14 through 
Figure 16 with assumed Ssu72 concentrations in Table 10. These data indicate that the 
L84A condition had a higher response than all other constructs when run at the 1 µM 
Protein Dilution Intensity
Protein 
Amount 
(µg)
Protein 
Concentration 
Adjusted for Dilution 
(mg/mL)
Ssu72 WT 2 11092.21 957.0 1.9
Ssu72 WT 5 5139.477 312.1 1.6
GST 2 12606.13 1121.1 2.2
GST 5 7867.77 607.7 3.0
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concentration of Ssu72. While the response values for L84F had a higher average 
response than WT, L84F and WT responses for this experiment were within 1 standard 
deviation from each other. In the case of the 10 µM Ssu72 condition, the response was 
too rapid too show difference between most constructs but there was differentiation 
between L84F and wild type at the first two readings. C15S and GST were all lower than 
the other constructs. 
 
Figure 14. Kinetic study #1 with all constructs at 1 µM Ssu72 and DiFMUP at 10 µM (1 
standard deviation shown) 
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Figure 15. Kinetic study #1 with all constructs at 1 µM Ssu72 and DiFMUP at 10 µM (1 
standard deviation shown) 
 
Figure 16. Kinetic study #1 with all constructs at 1 µM Ssu72 and DiFMUP at 10 µM, 
without L84A constructs (1 standard deviation shown) 
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Table 10. Assumed concentrations for kinetic study #1 
Construct Assumed Concentration (µg/µL) 
GST-WT 13.8 
GST-C15S 9.9 
GST-L84A 9.1 
GST-L84A2 4.9 
GST-L84F 3.1 
 
The second experiment kept DiFMUP concentration at 10 µM with Ssu72 concentrations 
of 0.25, 0.50, 1.0 and 2.0 µM. The time-course data for each of the constructs at the 2 
µM condition is shown below in Figure 17. These results show a more definitive 
separation between L84F and WT. 
 
Figure 17. Kinetic study #2 with all constructs at 2 µM Ssu72 and DiFMUP at 10 µM (1 
standard deviation shown) 
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The initial rate of change for each condition in this second experiment was calculated 
and the results are shown in Figure 18 and Figure 19. The assumed concentrations for 
the studies are shown in Table 11. These results reinforce the higher phosphatase 
activity for L84F over WT. 
 
Figure 18. Kinetic study #2 0 to 2 µM (1 standard deviation shown) 
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Figure 19. Kinetic study #2 0 to 2 µM (1 standard deviation shown), 0 to 2 µM, zoomed 
in (1 standard deviation shown) 
Table 11. Assumed concentrations for kinetic study #2 
Construct Assumed Concentration (µg/µL) 
GST-WT 13.8 
GST-C15S 9.9 
GST-L84A 9.1 
GST-L84A2 4.9 
GST-L84F 3.1 
 
The data from the 2 µM kinetic study was also analyzed in order to address whether 
there was a difference between the cleaved Ssu72 and the GST tagged protein. The 
time course results from the replicates are shown in Figure 20.  
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Figure 20. Relative Fluorescence vs. time for cleaved and GST tagged constructs at 2 
µM 
Data points were analyzed by Grubb’s test to determine if each cleaved construct was 
an outlier when compared to the other GST-tagged constructs. More specifically, the 
final data point at 2 hours was used in the analysis due to the fact that the data points 
were furthest from the GST-tagged constructs in the data set and that this analysis 
would be worst case. As shown in Figure 21, G-crit is greater than G in both cases and 
consequently, the data points are not considered to be outliers when compared to the 
GST-tagged responses at 2 hours.  
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Figure 21. Grubb’s test analysis for cleaved Ssu72 (replicate #1 left, replicate #2 right) 
The phosphatase activity of the Ssu72 constructs was also measured in the DiFMUP 
assay by varying substrate concentration while keeping phosphatase concentration 
constant at 2 µM. The DiFMUP study was completed using a biological replicate of 
Ssu72 L84F (L84F#2) since L84F samples had been consumed by this time in the 
research.  
 
Grubbs Test
Values min 563.248
WT 833.552 mean 828.2526
WT 563.248 stdev 200.7201
WT 897.523 G 1.320269
WT 739.123
C-WT 1107.817 alpha 0.05
size 5
sig value 0.01
df 3
t-crit 4.540703
G-crit 1.671386
sig value No
Grubbs Test
Values min 563.248
WT 833.552 mean 785.9664
WT 563.248 stdev 140.2672
WT 897.523 G 1.587815
WT 739.123
C-WT 896.386 alpha 0.05
size 5
sig value 0.01
df 3
t-crit 4.540703
G-crit 1.671386
sig value No
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One of the challenges with the DiFMUP varied concentration experiment was that there 
were two ~ 25 kD molecular weight bands that were observed by SDS-PAGE (Figure 11) 
when the L84F construct was analyzed. Based on work shown in Figure 13, it was 
suggested that these two extra bands could be the cleaved forms of GST and Ssu72. 
The identity of these bands, however, was not definitive and therefore two approaches 
were taken for conducting the kinetic phosphatase measurements. In the first 
experiment, the smaller bands were included in the calculation of total Ssu72 with the 
assumption that all bands contributed to the phosphatase activity. In the case of the 
second calculation, only the band at around 50 kD was included in the calculation with 
the assumption that only this fraction had phosphatase activity (shown in Figure 12).b   
The first DiFMUP varied experiment used the assumption of 7.9 mg/mL for Ssu72 
concentration while the second DiFMUP varied experiment assumed a concentration of 
1.8 mg/ml. In the case of each experiment, the initial rate of fluorescence change was 
measured for each concentration of substrate. As shown in Figure 22 and Figure 23 
(with concentrations in Table 12), the L84A replicates had a much higher rate of RFU 
change when compared to the other three constructs. While the mean response for 
L84F#2 was also greater than wild type in every data point, there was overlap between 
points when the standard deviation was accounted for. 
                                                          
b The same lane that was used in the first calculation was used in this second calculation despite 
the fact that the intensity of the 50 kD band was less than the bottom intensity on the BSA 
calibration curve. If the lane to the left would have been used, the calculated concentration would 
have been 2.3 mg/mL. 
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Figure 22. Kinetic study #3, L84F#2 = 7.9 mg/mL (1 standard deviation shown), with 
L84A 
 
Figure 23. Kinetic study #3, L84F#2 = 7.9 mg/mL (1 standard deviation shown), without 
L84A 
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Table 12. Concentrations in Kinetic Study #3 
Construct Assumed Concentration (µg/µL) 
GST-WT 13.8 
GST-C15S 9.9 
GST-L84A 9.1 
GST-L84A2 4.9 
GST-L84F2 7.9 
 
Figure 24 below (along with corresponding concentrations in Table 13) shows the results 
from the analysis that assumed a lower concentration of 1.8 mg/mL. These results show 
clear separation and higher rate of activity for the L84F#2 construct than for wild type.  
 
Figure 24. Kinetic Study #4, L84F#2 = 1.8 mg/mL (1 standard deviation shown) 
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Table 13. Concentrations in Kinetic Study #4 
Construct Assumed Concentration (µg/µL) 
GST-WT 13.8 
GST-C15S 9.9 
GST-L84A 9.1 
GST-L84A2 4.9 
GST-L84F2 1.8 
 
VI. Biotinylated Pulldown 
The overall goal of the biotinylated pulldown assay was to determine whether the 
recombinantly produced Ssu72 constructs would associate with a CTD peptide. More 
specifically, there was a goal of determining whether the strength of interaction between 
the CTD peptide and the wild type Ssu72 differed clearly from the L84F Ssu72 construct. 
Results from SDS-PAGE analysis using Coomassie staining are shown in Figure 25. In 
the case of each supernatant lane, the bands present near 50 kD and 25 kD (in the case 
of the cleaved WT and GST) suggest that there were fairly consistent levels of Ssu72 
protein in each sample as it was combined with the biotinylated CTD (lanes labeled as 
“Supernatant” or “Super”). The release step lanes (labeled as “Release”) show the levels 
of Ssu72 protein that were present after release of the protein from the biotinylated 
peptide. Each of these bands near 50 kD and 25 kD were very faint. 
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Figure 25. Biotinylated pulldown analysis by SDS PAGE and Coomassie stain 
Due to the fact that the bands were difficult to see in the visualized gel, the picture file 
was also analyzed using the ImageJ software in order to quantitate the color density of 
these bands as detected by the scanner. The results from this analysis are shown in 
Figure 26 and indicate that in the case of every construct, there was a measurable level 
of association between the CTD peptide and the Ssu72 protein. 
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Figure 26. ImageJ Analysis of Pulldown Gel 
 
VII. Analysis of FLAG Tagged Ssu72 Protein by SDS-PAGE and Silver Stain 
The 3X FLAG Ssu72 proteins isolated from the expression and purification were first 
analyzed by SDS-PAGE with silver staining. The first ethanol wash consisted of 100% 
ethanol instead of the diluted formulation. After the ethanol wash, a water wash was 
done followed by the planned 30% ethanol formulation followed by the balance of the 
planned wash steps. Elutions were further analyzed by SDS-PAGE gel and silver 
staining; silver stained gels from the 3X FLAG Ssu72 Wild Type construct are shown in 
Figure 27 which shows a large number of bands from each of elution. Results below 
suggest that the expression and purification was successful from the standpoint that a 
large number of proteins were isolated from the procedure.  
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Figure 27. Elutions from 3X FLAG tagged Wild Type Ssu72 
 
VIII. Analysis of FLAG-Ssu72 WT by LC-MS/MS 
FLAG-tagged Ssu72 elutions 2 and 3 from the purification described in the section 
above were TCA precipitated and the precipitated protein was reduced and alkylated by 
TCEP and CAM. The protein was then digested by Endoproteinase Lys-C and Trypsin 
Gold followed by quenching with formic acid. The sample was loaded on a fused silica 
glass column was packed with reverse phase C18, 2.5 cm of strong cation exchange 
resin and 2.25 cm of C18. A10 step MudPIT method was performed on the column and 
data collected was analyzed by Scaffold. Steps 2 through 4 of the data set were queried 
further while using a 5.0% peptide false discovery rate (FDR), 95% protein threshold and 
2 minimum peptides to identify a protein. 
 
The Ssu72 protein was identified in the analysis indicating that the expression afforded 
the desired protein. One of the Ssu72 peptides detected with a high correlation was 
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VLQEAGYNVSSYGTGSAVR; the MS/MS fragment ion spectrum for this peptide is 
shown below in Figure 28. 
   
 
Figure 28. MS/MS spectrum for Ssu72 peptide fragment detected in fraction #2 
(VLQEAGYNVSSYGTGSAVR) 
Many proteins have been previously shown to be associated with the Ssu72 
phosphatase in-vivo. Proteins that have been reported to physically associate with a 
TAP tagged Ssu72 are Cft1, Cft2, Ysh1, Pta1, Ref2, Pap1, Mpe1, Pfs2, Fip1, Pti1, 
Swd2, Glc7, Yth1 and Syc1(E. Nedea et al., 2003); each components of the cleavage 
and polyadenylation factor (CPF) complex. Peptides from five of these 14 proteins were 
detected in the LC-MS/MS analysis and these spectra along with their correlations are 
shown below in Figure 29 through Figure 33. Overall these results suggested that the 
MudPIT experiment was successful in that it detected peptides for Ssu72 along with 
other components of the cleavage and polyadenylation factor complex. At the same 
time, protein concentrations were low and would need to be increased in order to make 
better conclusions about what subunits of the CPF complex can be detected in the 
assay.  
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Figure 29. MS/MS spectrum for Cft1peptide detected in fraction #2 
((R)LNATNSNKNmDLFIGFGSGNALVLR(L)) 
 
Figure 30. MS/MS spectrum for Cft2 peptide detected in fraction #2 (ISDSYTVATVVGR) 
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Figure 31. MS/MS spectrum for Ysh1 peptide detected in fraction #2 
(FFSLGGSNEVGR) 
 
Figure 32. MS/MS spectrum for Pfs2 peptide detected in fraction #2 
(INGWFFGINNDINAVR) 
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Figure 33. MS/MS spectrum for Pti1 peptide detected in fraction #2 
(DSYPFEAGLELPFEMVTEVPIPR) 
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DISCUSSION 
The overall goal of this work was to determine whether the phosphatase activity of 
Ssu72 TOV mutant (as measured by an in-vitro assay) can explain the Ssu72 L84F 
mutant phenotype of termination deficiency. As presented in this report, the phosphatase 
activity of the GST tagged Ssu72 proteins, as measured by DiFMUP substrate, is 
impacted by mutations made to the L84 residue. The mutation of leucine to alanine at 
residue 84 in general displays the highest level of phosphatase activity when compared 
to the other constructs tested. In experiments presented, the L84F mutation has equal or 
higher phosphatase activity than the wild type construct (by the in-vitro assay) and in no 
case was the measured activity lower for L84F than wild type Ssu72. The catalytically 
dead Ssu72 construct (cysteine to serine mutation at residue 15) shows activity lower 
than wild type as expected. 
 
The increase in phosphatase activity for L84F Ssu72 is potentially the result of an 
improved association between Pol II CTD and Ssu72 due to pi-pi stacking interactions. 
This suggested relationship is based on both the observed activity by the DiFMUP 
substrate coupled with data from published crystal structures for the Ssu72 protein using 
Drosophila melanogaster and Homo sapiens homologue (Luo et al., 2013; Mayfield et 
al., 2015a; Werner-Allen et al., 2011; Xiang et al., 2012; Xiang et al., 2010; Y. Zhang, 
Zhang, & Zhang, 2011).c   
                                                          
c It should be noted that none of the structures published to date have used the Saccharomyces 
cerevisiae homologue due to challenges with crystallization of yeast Ssu72. In order to use the 
structural information published from the two available species in analysis, a sequence and 
structural comparison was first conducted. There is alignment between Saccharomyces 
cerevisiae, Homo sapiens and Drosophila melanogaster forms; 35% identity, 72 similar positions 
and 66 similar positions based on the Clustal algorithm (Soding, 2005). The alignment analysis 
suggested that yeast Ssu72 could be understood at a rudimentary level by the Drosophila and 
Human homologues. 
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Ssu72 structures published with a CTD peptide bound to the catalytic groove of the 
phosphatase were viewed for both the Drosophila and human homologues. A Drosophila 
structure (4YGX) (Mayfield et al., 2015a) and human structure (3O2Q) (Xiang et al., 
2010) viewed in NCBI Cn3D 4.3.1 are shown in Figure 34. 
 
Figure 34. 4YGX (Left) and 3O2Q (Right) with Ssu72 L82 and I81 highlighted yellow and 
CTD peptide colored gray 
The two crystal structures, 4YGX and 3O2Q, were rendered and compared using 
WinCoot version 0.8.2 (as shown below in Figure 35 and Figure 36) to visualize some of 
the interactions at the corresponding residues. As shown in these figures below, the wild 
type leucine or isoleucine in Ssu72 for the two species are more distant from the CTD 
peptide (4.4 and 4.6 Angstroms respectively) than the mutated Ssu72 phenylalanine (4.0 
and 3.2 Angstroms respectively) that was generated using the mutation function in 
WinCoot. It is possible that the proline in the CTD is interacting with the phenylalanine by 
pi-pi interactions. Reports suggest that proline can participate in pi-pi stacking with other 
aromatic side chains (Zondlo, 2013) and that 3.4 Angstroms is a good approximation for 
distance of the interactions (Hunter & Sanders, 1990).  
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Figure 35. 4YGX, Drosophila melanogaster L82 residue (Top) and 3O2Q, Homo sapiens 
I81 residue (Bottom) and distance to CTD peptide in crystal structure 
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Figure 36. 4YGX, Drosophila melanogaster L82F mutation (Top) and 3O2Q, Homo 
sapiens I81F mutation (Bottom) and distance to CTD peptide in crystal structure 
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In the case of the Ssu72 L84A mutation (as shown in Figure 37), it is unclear why this 
mutation results in such an extremely high level of activity as measured by the DiFMUP 
assay. As shown below, the mutation potentially results in a greater distance between 
the Ssu72 residue and the CTD peptide. It is possible that the mutation affects the 
tertiary structure of the Ssu72 protein and causes the CTD to be more accessible to the 
catalytic cysteine site. On the other hand, it is possible that the L84A activity by the 
DiFMUP assay is not representative of the in-vivo response. In other words, it is quite 
possible that termination override would not be observed in this L84A condition. Despite 
this contradiction between phosphatase response and suggested interactions by crystal 
structures, it can be seen that the L84 residue has a good potential for impacting the 
interaction with the Pol II CTD.   
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Figure 37. 4YGX, Drosophila melanogaster L82A mutation (Top) and 3O2Q, Homo 
sapiens I81A mutation (Bottom) and distance to CTD peptide in crystal structure 
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It should be noted that data from Zhang showed that L82A mutation in a Drosophila 
homologue had no loss in phosphatase activity (by PNPP mimetic substrate) or loss of 
CTD substrate specificity (Y. Zhang et al., 2011) when compared to wild type. The 
studies presented in this report suggest a possible increase in activity for L84F Ssu72 
when compared to Ssu72 WT. It has also been observed in unpublished studies within 
the Mosley lab that serine 5 CTD phosphorylation levels were lower for a SSU72-TOV 
containing S. cerevisiae strain. On the other hand, if the L84F mutation doesn’t actually 
increase phosphatase activity but instead maintains the same phosphatase activity as 
WT, it is possible that the mutation impacts some other interaction with the CPF complex 
or RNA Pol II. Data from the pull-down approach suggests that all of GST-Ssu72 
homologues tested, including the L84F mutant, are able to associate with the CTD 
(based on results with a CTD peptide). At the same time, GST alone associated with the 
CTD peptide and reinforces the need for re-execution of the method with GST cleaved 
forms of Ssu72.  
 
Another possibility is that the Ssu72 L84F mutation actually affects interactions with 
other CPF subunits. The results from the ex-vivo approach with mass spec analysis 
suggest that the use of a FLAG tagged Ssu72 is suitable approach for determining 
physical interactions between the Ssu72 protein and other CPF subunits. The presence 
of the five detected subunits agrees with external reports showing that Ssu72 is stably 
associated with the CPF complex. At the same time, the number of proteins that were 
observed along with their intensity indicate that the experiment could be improved with 
higher concentrations of protein. The utility of FLAG tagged Ssu72 expression and 
MudPIT analysis could further be leveraged in the future by comparing results with those 
from a similar experiment where the TOV mutant is used instead of the WT expressing 
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cell line. The mass spec comparative analysis would allow for understanding the 
influence of the L84F mutation on the physical interaction with other CPF components 
and consequently help to understand if the mutation causes other changes in the 
transcription process. 
 
The ultimate goal of our work, however, is to explain the impact of the L84F mutation on 
the observed termination override (TOV) described by the Reines lab. One possible 
explanation for the observed TOV is that the mutation affects association with 
termination factors. Ssu72 is associated with termination of snoRNA, (M. Kim et al., 
2006; Steinmetz & Brow, 2003) and the termination of these non-coding transcripts has 
been reported to be associated with the NNS pathway (Nrd1, Nab3, Sen1). The NNS 
pathway is described pictorially below in Figure 38.  
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Figure 38. NNS pathway and association with DNA transcription termination by RNA Pol 
II 
It has been reported that Nrd1 binds to Ser-5 phosphorylated CTD (Vasiljeva et al., 
2008). If the phosphatase activity of the L84F mutant is slightly elevated over the wild 
type Ssu72, it is possible that the lower level of Ser-5 phosphorylation of the CTD results 
in less efficient docking of the NNS complex to the CTD. Concomitantly, if the CTD 
binding domain of Nrd1 cannot bind to RNA Pol II CTD, it is possible that decreased 
binding could lead to ineffective termination; this theory is reinforced by the fact that 
mutations of Nrd1 have been connected with termination read-through in other reports 
(Vasiljeva & Buratowski, 2006). Read-through was also reported when the C-terminal 
interacting domain (CID) of Nrd1 was mutated (Heo et al., 2013). Overall, if it is assumed 
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that the activity of L84F increases the phosphatase activity of Ssu72 when compared to 
wild type Ssu72, the model for termination override can be described by Figure 39 
below. 
 
Figure 39. Model of transcription termination and read-through via interactions with both 
NNS and CPF/Ssu72 
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CONCLUSIONS 
It can be concluded from this work that the L84F mutation in the Ssu72 yeast isoform 
causes an equivalent or increase in in-vitro phosphatase activity as compared to wild 
type. It was also shown from this work that the L84A mutation in the yeast isoform 
causes an even greater increase in in-vitro phosphatase activity and further reinforces 
that the L84 residue influences activity of the phosphatase. One theory for the increased 
activity observation is that the leucine to phenylalanine mutation improves Ssu72 
substrate access. This may be true for both small molecule substrates such as DiFMUP 
as well as the RNA Pol II CTD. The ultimate goal of this work, however, is to explain the 
impact of the L84F mutation on the observed termination override (TOV) mutant of 
Ssu72. One possible explanation for the observed TOV is that the L84F mutation results 
in lower serine 5 phosphorylation (due to higher phosphatase activity when compared to 
wild type Ssu72) which decreases the association of termination factors such as Nrd1 
with Pol II (leading to inefficient termination). The conclusions highlighted in this report 
could be improved with further suggested work. It is recommended that more proteomics 
work be used to orthogonally describe the TOV mutant, which would allow for 
understanding whether the L84F mutation impacts the association of the phosphatase 
with other CPF subunits. It would also be beneficial to crystallize the Ssu72 mutant 
constructs in the presence of a CTD peptide to confirm whether the observed 
phosphatase activity can be supported. Human and Drosophila homologues have 
already been crystallized and it would be advantageous to use this existing work (since 
molecular replacement and existing crystallization conditions could be leveraged).  
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